June 30 (Reuters) - AbbVie (ABBV.N), opens new tab said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product ...
"Marshall’s rich experience strengthens our board as we move into our next phase of growth," CEO Maggie Nixon said.
AbbVie is making a full strength play for the in vivo CAR-T market, snapping up Capstan Therapeutics for $2.1 billion to add an early-phase autoimmune drug candidate to its pipeline. Capstan is part ...
AbbVie has agreed to acquire Capstan Therapeutics for up to $2.1bn, adding a “high-risk, high-reward” clinical-stage in vivo CAR-T candidate to its pipeline. Capstan is developing a new type of CAR-T ...
A University of Pennsylvania biotechnology company that aims to treat autoimmune diseases by reengineering cells within the body is being acquired by pharmaceutical giant AbbVie for $2.1 billion in ...
SAN DIEGO--(BUSINESS WIRE)--Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery utilizing targeted lipid ...
SAN DIEGO & PHILADELPHIA--(BUSINESS WIRE)--Capstan Therapeutics, Inc., a biotechnology company dedicated to developing and delivering precise in vivo cell engineering to patients, launched today with ...
AbbVie announced this morning it would buy clinical-stage biotech company Capstan Therapeutics for up to $2.1 billion in cash, picking up the company's in vivo CAR-T therapy candidate. San Diego-based ...
Capstan Medical, a developer of robotic-enabled, minimally invasive solutions to address heart valve disease, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback